Prognostic value of the advanced lung cancer inflammation index in intrahepatic cholangiocarcinoma.

Cancer surgery Cholangiocarcinoma Inflammation Malnutrition

Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
18 Oct 2024
Historique:
received: 10 09 2024
revised: 08 10 2024
accepted: 15 10 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 24 10 2024
Statut: aheadofprint

Résumé

The advanced lung cancer inflammation index (ALI), which combines inflammation and nutrition data, was recently proposed as a prognostic biomarker. We assessed the impact of ALI on overall survival (OS) among patients undergoing surgery for intrahepatic cholangiocarcinoma (ICC). Patients who underwent surgery for ICC were identified from an international cohort. ALI was calculated as body-mass index (BMI)∗albumin/neutrophil-to-lymphocyte ratio; patients were categorized into "low-" and "high-ALI" using log-rank statistics. The impact of ALI on OS was compared against other inflammatory markers (i.e., neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], systemic immune inflammation index [SII = platelets∗NLR]) using Harrell's Concordance index (C-index) and the Akaike Information Criterion (AIC). To minimize intergroup differences, propensity score matching was employed. Among 1045 patients, more than one-half of individuals underwent major hepatectomy (n = 582, 55.7 %), median tumor size was 5.5 cm (IQR, 3.8-7.8), and median ALI was 38.9 (IQR 26.5-57.2). On multivariate analysis, low ALI was an independent risk factor for worse OS (HR 1.21, 95 % CI 1.01-1.46; p = 0.04). Patients with low ALI had worse 5-year OS (36.9 % vs. 49.9 %; p < 0.001), which remained significant after PSM (36.9 % vs. 41.3 %; p = 0.039). ALI had a comparable discriminatory ability compared with NLR, PLR, and SII (C-index: 0.646 vs. 0.644 vs. 0.640 vs. 0.641, respectively), yet had a lower AIC (5475.31 vs. 5546.80 vs. 5550.45 vs. 5548.62, respectively) suggesting slightly better model fit and accuracy. ALI was an independent predictor of OS among patients undergoing surgery for ICC. Nutritional and inflammatory markers should be incorporated into predictive models to improve prognostic stratification.

Identifiants

pubmed: 39447453
pii: S0748-7983(24)00840-0
doi: 10.1016/j.ejso.2024.108773
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108773

Informations de copyright

Copyright © 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Giovanni Catalano (G)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Surgery, University of Verona, Verona, Italy.

Laura Alaimo (L)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Department of Surgery, University of Verona, Verona, Italy.

Odysseas P Chatzipanagiotou (OP)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Andrea Ruzzenente (A)

Department of Surgery, University of Verona, Verona, Italy.

Federico Aucejo (F)

Cleveland Clinic Foundation, Digestive Diseases and Surgery Institute, Department of Hepato-pancreato-biliary & Liver Transplant Surgery, Cleveland, OH, USA.

Hugo P Marques (HP)

Department of Surgery, Curry Cabral Hospital, Lisbon, Portugal.

Vincent Lam (V)

Department of Surgery, Westmead Hospital, Sydney, Australia.

Tom Hugh (T)

Department of Surgery, The University of Sydney, School of Medicine, Sydney, Australia.

Nazim Bhimani (N)

Department of Surgery, The University of Sydney, School of Medicine, Sydney, Australia.

Shishir K Maithel (SK)

Division of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Minoru Kitago (M)

Department of Surgery, Keio University, Tokyo, Japan.

Itaru Endo (I)

Yokohama City University School of Medicine, Yokohama, Japan.

Guillaume Martel (G)

Department of Surgery, University of Ottawa, Ottawa, ON, Canada.

Carlo Pulitano (C)

Department of Surgery, Royal Prince Alfred Hospital, University of Sydney, Sydney, NSW, Australia.

Feng Shen (F)

Department of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.

Irinel Popescu (I)

Department of Surgery, Fundeni Clinical Institute, Bucharest, Romania.

Bas Groot Koerkamp (BG)

Department of Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands.

Todd W Bauer (TW)

Department of Surgery, University of Virginia, Charlottesville, VA, USA.

François Cauchy (F)

Department of Hepatobiliopancreatic Surgery and Liver Transplantation, AP-HP, Beaujon Hospital, Clichy, France.

George A Poultsides (GA)

Department of Surgery, Stanford University, Stanford, CA, USA.

Matthew Weiss (M)

Department of Surgery, Cancer Institute, Northwell Health, NY, USA.

Ana Gleisner (A)

Department of Surgery, UC Denver, Denver, CO, USA.

Timothy M Pawlik (TM)

Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: Tim.Pawlik@osumc.edu.

Classifications MeSH